This is aimed at rapidly advancing the innovation pipeline. One of the most promising Phase 3 candidates is AMGN’s MariTide drug for obesity. Management highlighted progress around this and ...

Though the company's leading candidate in this field, MariTide, didn't quite live up to market expectations in a phase 2 clinical trial, it's too early to give up on this project. The company is ...

There is also anticipation building for MariTide, its experimental obesity drug entering phase 3 trials, which could position the company to enter the GLP-1 weight loss and diabetes market.

Fitch anticipates that Amgen will maintain these levels in the medium to long term. The successful launch of the obesity drug Maritide and a favorable resolution of ongoing tax litigation could ...

Structure Therapeutics' stock has declined ... while Amgen's drug candidate MariTide blocks GIP as opposed to stimulating it as tirzepatide does. It may take years and many more clinical studies ...